At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
OS Onestream Inc
Market Closed 12-20 16:00:00 EST
29.66
+0.04
+0.14%
盘后29.59
-0.07-0.24%
18:25 EST
High30.54
Low28.40
Vol2.88M
Open29.10
D1 Closing29.62
Amplitude7.22%
Mkt Cap4.96B
Tradable Cap939.49M
Total Shares167.28M
T/O85.41M
T/O Rate9.09%
Tradable Shares31.68M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium